Q2 Earnings Forecast for Celcuity Issued By Leerink Partnrs

Celcuity Inc. (NASDAQ:CELC) – Equities researchers at Leerink Partnrs issued their Q2 2025 earnings per share estimates for Celcuity in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will earn ($0.85) per share for the quarter. The consensus estimate for Celcuity’s current full-year earnings is ($2.62) per share.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Celcuity in a research note on Friday, November 15th. Needham & Company LLC boosted their price target on Celcuity from $23.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $30.17.

Celcuity Stock Down 2.7 %

CELC opened at $12.25 on Friday. Celcuity has a 12 month low of $10.35 and a 12 month high of $22.19. The business has a 50-day moving average of $12.31 and a two-hundred day moving average of $14.45. The stock has a market capitalization of $454.84 million, a price-to-earnings ratio of -4.69 and a beta of 0.73. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36.

Institutional Investors Weigh In On Celcuity

A number of institutional investors have recently made changes to their positions in CELC. SG Americas Securities LLC acquired a new position in Celcuity in the third quarter valued at approximately $119,000. nVerses Capital LLC bought a new stake in shares of Celcuity in the 3rd quarter worth approximately $33,000. Hennion & Walsh Asset Management Inc. boosted its position in Celcuity by 34.7% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 73,026 shares of the company’s stock valued at $1,089,000 after purchasing an additional 18,809 shares during the period. Values First Advisors Inc. bought a new position in Celcuity during the 3rd quarter worth $86,000. Finally, Quest Partners LLC increased its position in Celcuity by 227.6% in the third quarter. Quest Partners LLC now owns 18,962 shares of the company’s stock worth $283,000 after buying an additional 13,174 shares during the period. 63.33% of the stock is currently owned by institutional investors.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.